RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+17.81%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.3B
AUM Growth
+$5.3B
(+20%)
Cap. Flow
+$279M
Cap. Flow
% of AUM
5.26%
Top 10 Holdings %
Top 10 Hldgs %
58.3%
Holding
63
New
4
Increased
10
Reduced
3
Closed
9
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$381M |
| 2 |
Legend Biotech
LEGN
|
$264M |
| 3 |
Axsome Therapeutics
AXSM
|
$71.9M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$59.5M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$55.5M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$368M |
| 2 |
BLU
BELLUS Health Inc.
BLU
|
$91M |
| 3 |
Celldex Therapeutics
CLDX
|
$62.4M |
| 4 |
HilleVax
HLVX
|
$29.1M |
| 5 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$26.7M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $1B | 18.92% | 11,225,357 +4,268,178 | +61% | +$381M |
|
|
2
Legend Biotech
LEGN
$6.41B
| $432M | 8.16% | 6,264,707 +3,828,484 | +157% | +$264M |
|
3
Vaxcyte
PCVX
$4B
| $394M | 7.44% | 7,891,254 +600,000 | +8% | +$30M |
|
|
DICE
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $365M | 6.89% | 7,856,612 | – | – |
|
5
89bio
ETNB
$1.34B
| $216M | 4.08% | 11,416,948 | – | – |
|
6
Biogen
BIIB
$19.4B
| $152M | 2.87% | 532,892 | – | – |
|
|
JBIO
7
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $142M | 2.68% | 8,263,982 | – | – |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $134M | 2.52% | 6,317,990 | – | – |
|
9
CureVac
CVAC
$1.21B
| $128M | 2.41% | 12,245,955 | – | – |
|
10
Tyra Biosciences
TYRA
$675M
| $123M | 2.33% | 7,236,454 | – | – |
|
|
11
NewAmsterdam Pharma
NAMS
$2.71B
| $107M | 2.02% | 9,000,000 +5,000,000 | +125% | +$59.5M |
|
12
Cytek Biosciences
CTKB
$527M
| $105M | 1.98% | 12,297,721 -1,083,333 | -8% | -$9.25M |
|
13
Janux Therapeutics
JANX
$1.37B
| $103M | 1.94% | 8,670,644 | – | – |
|
14
Geron
GERN
$893M
| $101M | 1.91% | 31,544,806 | – | – |
|
|
INBX
15
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $100M | 1.89% | 3,853,867 | – | – |
|
16
Rhythm Pharmaceuticals
RYTM
$6.85B
| $93.6M | 1.77% | 5,676,067 +160,000 | +3% | +$2.64M |
|
17
Day One Biopharmaceuticals
DAWN
$769M
| $93.2M | 1.76% | 7,809,852 +769,230 | +11% | +$9.18M |
|
18
RxSight
RXST
$370M
| $87.9M | 1.66% | 3,052,796 | – | – |
|
19
Cogent Biosciences
COGT
$1.69B
| $76M | 1.43% | 6,416,147 +416,666 | +7% | +$4.93M |
|
20
PepGen
PEPG
$38M
| $72.7M | 1.37% | 8,131,952 | – | – |
|
|
21
Axsome Therapeutics
AXSM
$6.05B
| $71.9M | 1.36% | +1,000,000 | New | +$71.9M |
|
22
Avidity Biosciences
RNA
$5.99B
| $71.2M | 1.34% | 6,416,998 | – | – |
|
23
Vor Biopharma
VOR
$250M
| $70.3M | 1.33% | 22,748,880 | – | – |
|
24
GH Research
GHRS
$837M
| $66.3M | 1.25% | 5,587,333 +6,172 | +0.1% | +$73.2K |
|
25
Wave Life Sciences
WVE
$1.53B
| $62.6M | 1.18% | 17,202,009 | – | – |
|